References
Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Marina Pollán, Beatriz Pérez-Gómez, Roberto Pastor-Barriuso, Jesús Oteo, Miguel A Hernán, Mayte Pérez-Olmeda , Jose L Sanmartín, Aurora Fernández-García, Israel Cruz, Nerea Fernández de Larrea, Marta Molina, Francisco Rodríguez-Cabrera, Mariano Martín, Paloma Merino-Amador, Jose León Paniagua, Juan F Muñoz-Montalvo, Faustino Blanco, Raquel Yotti, on behalf of the ENE-COVID Study Group* The Lancet 2020, 366: 535-544.
Humoral immune response to SARS-CoV-2 in Iceland. Daniel F. Gudbjartsson, Ph.D.,
Gudmundur L. Norddahl, Ph.D., Pall Melsted, Ph.D., Kristbjorg Gunnarsdottir, M.Sc., Hilma Holm, M.D. et al. N. Engl. J. Med 2020; 383: 1724-1734 DOI: 10.1056/NEJMoa2026116
Institute for Government analysis (2021) ‘Timeline of UK government coronavirus lockdowns and measures, March 2020 to December 2021’. Available at: https://www.instituteforgovernment.org.uk/ sites/ default/ files/ timeline-coronavirus-lockdown-december-2021.pdf [Tip: hold Ctrl and click a link to open it in a new tab. (Hide tip)] Accessed: 11 February 2023
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults, to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19. https://clinicaltrials.gov/ ct2/ show/ study/ NCT04516746
Wei, J., Pouwels, K.B., Stoesser, N. et al. Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines. Nat Med (2022).
https://doi.org/ 10.1038/ s41591-022-01721-6
Viana, R., Moyo, S., Amoako, D.G. et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature 603, 679–686 (2022). https://doi.org/ 10.1038/ s41586-022-04411-y
Zhanwei Du, Caifen Liu, Chunyu Wang et al. Reproduction numbers of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variants: A systematic review and metaanalysis . Clinical Infectious Diseases, 75, e293–e295. https://doi.org/ 10.1093/ cid/ ciac137
Weisblum Y, Schmidt F, Zhang F, DaSilva J et al. Escape form neutralizing antibodies by SARS-CoV-2 spike protein variants. eLife 9:e61312. https://elifesciences.org/ articles/ 61312